Analysis of genotype and age distribution of cervical human papillomavirus infection in Futian District, Shenzhen, China

Our study aims to understand the prevalence of cervical HPV (Human papilloma virus) infection, different subtypes causing infection and age distribution characteristics of women in Futian District, Shenzhen, China, to provide a reference for effective local prevention and treatment of HPV and targeted development and application of the HPV vaccine. Information on HPV results, age and HPV genotypes infected were collected and retrospectively analysed among women who attended the free cervical cancer screening programme conducted by the Shenzhen Futian District Government between 01 January 2016 and 31 December 2022 at our gynaecology outpatient clinics and medical check-up centres. There were 2792 positive cases among 27,738 females in Futian District, Shenzhen, with a positivity rate of 10.07%. Types 52, 58, 16, 68, 51, 39, 18, 31 and 33 were the top 9 infected genotypes in Futian District, Shenzhen, China. The high prevalence of these three genotypes, HR-HPV (High-risk human papilloma virus) types 68, 51 and 39, in the region is an important finding. Age-related differences in HPV infection rates were considerable, with the bimodal peak of the infection rate curve occurring in the age ranges of 30–34 and 60–65. The distribution of cervical HPV infection types in each region is unique, and different age groups have their susceptibility to different HPV genotypes. Geographical and age specificity should be considered in the therapeutic usage of vaccinations.

Human papillomavirus; Genotype distribution; Age distribution; Cervical cancer

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nature Reviews. Microbiology. 2022; 20: 95–108.

[3] Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Archives of Gynecology and Obstetrics. 2020; 302: 1329–1337.

[4] Johnson CA, James D, Marzan A, Armaos M. Cervical cancer: an overview of pathophysiology and management. Seminars in Oncology Nursing. 2019; 35: 166–174.

[5] Lei J, Arroyo-Mühr LS, Lagheden C, Eklund C, Nordqvist Kleppe S, Elfström M, et al. Human papillomavirus infection determines prognosis in cervical cancer. Journal of Clinical Oncology. 2022; 40: 1522–1528.

[6] Scarth JA, Patterson MR, Morgan EL, Macdonald A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. Journal of General Virology. 2021; 102: 001540.

[7] Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination—review of current perspectives. Journal of Oncology. 2019; 2019: 1–11.

[8] Giannella L, Giorgi Rossi P, Delli Carpini G, Di Giuseppe J, Bogani G, Gardella B, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecologic Oncology. 2021; 161: 741–747.

[9] Li B, Wang H, Yang D, Ma J. Prevalence and distribution of cervical human papillomavirus genotypes in women with cytological results from Sichuan province, China. Journal of Medical Virology. 2019; 91: 139–145.

[10] Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Critical Reviews in Oncology/Hematology. 2022; 174: 103675.

[11] Yuan MW, Wang HH, Duan RF, Xu KP, Hu SY, Qiao YL, et al. Analysis on cancer incidence and mortality attributed to human papillomavirus infection in China, 2016. Zhonghua Liuxingbingxue Zazhi. 2022; 43: 702–708. (In Chinese)

[12] Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese Medical Journal. 2022; 135: 584–590.

[13] Lin X, Chen L, Zheng Y, Yan F, Li J, Zhang J, et al. Age-specific prevalence and genotype distribution of human papillomavirus in women from Northwest China. Cancer Medicine. 2022; 11: 4366–4373.

[14] Zhang H, Zhang S. Prevalence and genotype distribution of human papillomavirus infection among female outpatients in Northeast China: a population-based survey of 110,927 women. Archives of Gynecology and Obstetrics volume. 2023; 308: 35–41.

[15] Zhu X, Wang Y, Lv Z, Su J. Prevalence and genotype distribution of high-risk HPV infection among women in Beijing, China. Journal of Medical Virology. 2021; 93: 5103–5109.

[16] Chen T, Cai S, Lin J, Yang X, He X, Tu C, et al. Prevalence and genotype distribution of human papillomavirus among 29 263 women from the Longgang community of Shenzhen. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2022; 116: 173–178.

[17] Zeng Z, Austin RM, Wang L, Guo X, Zeng Q, Zheng B, et al. Nationwide prevalence and genotype distribution of high-risk human papillomavirus infection in China. American Journal of Clinical Pathology. 2022; 157: 718–723.

[18] Li M, Liu T, Luo G, Sun X, Hu G, Lu Y, et al. Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007–2018: a retrospective cohort study. Journal of Infection and Public Health. 2021; 14: 42–49.

[19] Liao G, Jiang X, She B, Tang H, Wang Z, Zhou H, et al. Multi-infection patterns and co-infection preference of 27 human papillomavirus types among 137,943 gynecological outpatients across China. Frontiers in Oncology. 2020; 10: 449.

[20] Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. a Cochrane review of randomized trials. Expert Review of Vaccines. 2018; 17: 1085–1091.

[21] Troja C, Hoofnagle AN, Szpiro A, Stern JE, Lin J, Winer RL. Understanding the role of emerging vitamin D biomarkers on Short-term persistence of high-risk human papillomavirus infection among mid-adult women. The Journal of Infectious Diseases. 2021; 224: 123–132.

[22] Shing JZ, Beeghly-Fadiel A, Griffin M R, Chang RS, Sudenga SL, Slaughter JC, et al. The impact of the human papillomavirus vaccine on high-grade cervical lesions in urban and rural areas: an age-period-cohort analysis. Cancers. 2021; 13: 4215.

[23] Ding L, Liu C, Zhou Q, Feng M, Wang J. Association of estradiol and HPV/HPV16 infection with the occurrence of cervical squamous cell carcinoma. Oncology Letters. 2019; 17: 3548–3554.

[24] Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, et al. Efficacy, Immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. The Journal of Infectious Diseases. 2018; 218: 95–108.

[25] Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against cancer. Vaccines. 2021; 9: 1413.

[26] Markowitz LE, Naleway AL, Klein NP, Lewis RM, Crane B, Querec TD, et al. Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses. The Journal of Infectious Diseases. 2020; 221: 910–918.

[27] Yin X, Zhang M, Wang F, Huang Y, Niu Y, Ge P, et al. A national cross-sectional study on the influencing factors of low HPV vaccination coverage in mainland China. Frontiers in Public Health. 2022; 10: 1064802.

[28] Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses. 2017; 9: 229.